KR101828613B1 - 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물 - Google Patents

올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물 Download PDF

Info

Publication number
KR101828613B1
KR101828613B1 KR1020127005885A KR20127005885A KR101828613B1 KR 101828613 B1 KR101828613 B1 KR 101828613B1 KR 1020127005885 A KR1020127005885 A KR 1020127005885A KR 20127005885 A KR20127005885 A KR 20127005885A KR 101828613 B1 KR101828613 B1 KR 101828613B1
Authority
KR
South Korea
Prior art keywords
daltons
compound
oligomer
quot
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127005885A
Other languages
English (en)
Korean (ko)
Other versions
KR20120090961A (ko
Inventor
제니퍼 릭스-소티어
린 청
데이비드 마틴
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20120090961A publication Critical patent/KR20120090961A/ko
Application granted granted Critical
Publication of KR101828613B1 publication Critical patent/KR101828613B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020127005885A 2009-09-29 2010-09-29 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물 Active KR101828613B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24693109P 2009-09-29 2009-09-29
US61/246,931 2009-09-29
PCT/US2010/050761 WO2011056325A2 (en) 2009-09-29 2010-09-29 Oligomer-calcimimetic conjugates and related compounds

Publications (2)

Publication Number Publication Date
KR20120090961A KR20120090961A (ko) 2012-08-17
KR101828613B1 true KR101828613B1 (ko) 2018-02-12

Family

ID=43901165

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005885A Active KR101828613B1 (ko) 2009-09-29 2010-09-29 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물

Country Status (9)

Country Link
EP (1) EP2482855B1 (enExample)
JP (1) JP5792175B2 (enExample)
KR (1) KR101828613B1 (enExample)
CN (1) CN102573921B (enExample)
AU (1) AU2010315805B2 (enExample)
CA (1) CA2773353C (enExample)
IL (1) IL218869A (enExample)
MX (1) MX341690B (enExample)
WO (1) WO2011056325A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
JP2020105072A (ja) * 2017-03-24 2020-07-09 協和キリン株式会社 ポリエチレングリコール誘導体
US20220040318A1 (en) * 2018-09-28 2022-02-10 Seikagaku Corporation Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
WO2022052471A1 (zh) * 2020-09-10 2022-03-17 陕西麦科奥特科技有限公司 双特异性融合多肽化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966988A (en) 1989-02-17 1990-10-30 Chevron Research Company Process for preparing acetonitrile 3-trifluoromethyl benzene
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
CN1925875A (zh) * 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US7250533B2 (en) 2005-05-16 2007-07-31 Teva Pharmaceutical Industries Ltd Process for preparing Cinacalcet hydrochloride
BRPI0611872B8 (pt) 2005-06-16 2021-05-25 Nektar Therapeutics reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
WO2007062147A1 (en) 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Crystal forms of cinacalcet hci and processes for their preparation
KR20080011320A (ko) 2006-04-27 2008-02-01 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염기의 제조 방법
US11033631B2 (en) * 2008-06-09 2021-06-15 Nektar Therapeutics Methods of treating CYP2D6 alternative metabolizers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders

Also Published As

Publication number Publication date
KR20120090961A (ko) 2012-08-17
CA2773353A1 (en) 2011-05-12
JP2013505966A (ja) 2013-02-21
CN102573921B (zh) 2015-11-25
CA2773353C (en) 2018-02-27
AU2010315805A1 (en) 2012-03-15
AU2010315805B2 (en) 2015-09-17
WO2011056325A3 (en) 2011-09-29
IL218869A0 (en) 2012-06-28
MX2012003775A (es) 2012-06-12
JP5792175B2 (ja) 2015-10-07
IL218869A (en) 2016-12-29
MX341690B (es) 2016-08-29
CN102573921A (zh) 2012-07-11
EP2482855B1 (en) 2017-12-27
EP2482855A2 (en) 2012-08-08
WO2011056325A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
EP2522367B1 (en) Oligomer-protease inhibitor conjugates
WO2012083153A1 (en) Oligomer-containing apremilast moiety compounds
JP5693967B2 (ja) オリゴマー−ジアリールピペラジンコンジュゲート
US20110112183A1 (en) Oligomer-Bis-Chromonyl Compound Conjugates
KR101828613B1 (ko) 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
US10265411B2 (en) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
JP5877553B2 (ja) オリゴマー−抗コリン剤複合体
WO2010132693A2 (en) Oligomer-containing pyrrolidine compounds
KR101799113B1 (ko) 올리고머를 함유하는 치환된 방향족 트리아진 화합물
JP2012502906A (ja) オリゴマー−プロテアーゼ阻害剤コンジュゲート
US9421275B2 (en) Oligomer-calcimimetic conjugates and related compunds
JP6265998B2 (ja) オリゴマー含有ベンズアミド系化合物
US9540330B2 (en) Oligomer-containing hydantoin compounds
EP2400989B1 (en) Gabapentin-peg conjugates

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9